The United States, unlike many developed countries with a national health service, lacks a uniform system to assess the value of drugs by insurers and a framework for describing decisions to key stakeholders. These issues were discussed during a session at the recent AMCP meeting. Read more here. (Source: First Report Eileen Koutnik-Fotopoulos, Managed Care, 11/2014).
